Business Wire

Chemours Announces Development of New Specialty Fluid for Two-Phase Immersion Cooling: Opteon™ 2P50

Share

The Chemours Company (“Chemours”) (NYSE: CC), a global chemistry company with leading market positions in Titanium Technologies, Thermal & Specialized Solutions, and Advanced Performance Materials, recently announced important achievements in the development and manufacture of Opteon™ 2P50, a new heat-transfer fluid for two-phase immersion cooling (2-PIC). The proprietary fluid is currently in the final testing stages for manufacturing capability, with initial commercialization targeted for 2025, pending appropriate regulatory approvals. Chemours’ Opteon™ 2P50 is a proprietary hydrofluoroolefin (HFO) dielectric fluid designed to meet the growing demand for high-performing products that reduce environmental impact while enabling circularity. Opteon™ 2P50 offers zero ozone depletion potential (ODP) and substantially lower global warming potential (GWP) compared to incumbent fluids.

Chemours’ introduction of Opteon™ 2P50 represents a critical step in positioning the company to meet a growing challenge brought on by a new era of data transmission driving a dramatic increase in demands for faster computing, AI capabilities, and other cutting-edge applications—all of which are based in technologies requiring elevated cooling capacities. Chemours’ new 2-PIC fluid enables high-performance computing and energy-efficient cooling across a broad range of thermal management applications.

“Two-phase immersion cooling represents a tremendous unmet market need and Chemours is excited to be entering this space and investing in the present and future needs in such a significant way,” said Natalia Duchini, Senior Director, Global Technology at Chemours. “We’ve innovated a next-generation fluid that meets or exceeds our customers’ most critical criteria for performance and efficiency. Moreover, by putting the power of our chemistry to work, it also ensures sustainability in an evolving environmental landscape.”

Worldwide, data centers currently account for approximately 1% of carbon emissions and approximately 1 to 1.5% of electricity consumption. More than 95% of data centers use traditional air- and water-cooling technologies. 2-PIC is the most sustainable, cost effective, and efficient alternative to traditional air-cooled data centers in terms of energy and water consumption. By submerging electronic equipment directly in a dielectric fluid, they can be cooled efficiently and safely, without the risk of hardware damage. Customer trials of Chemours Opteon™ 2P50 have confirmed outstanding performance.

2-PIC can reduce data center cooling energy consumption by more than 90% and nearly eliminate water use, reducing operating expenses. In addition, 2-PIC simplified cooling structure supports reduced capital expenditures by enabling up to a 60% reduction in the physical data center footprint, while ensuring optimum cooling capabilities to support next-generation high-performance computing applications. The ability to reclaim and reuse the two-phase immersion fluid also creates a clear path to a circular economy.

“We’re working to create more than just an incremental improvement,” said Duchini. “Our vision is to set a new industry standard with the performance and thermal stability of Opteon™ 2P50. In addition to playing a critical role in enabling 2-PIC technologies through enhanced thermal management performance, this new solution from Chemours will enable businesses and entire industries to reduce their physical footprint and environmental impact.”

Chemours Opteon™ 2P50 fluid for 2-PIC is aligned with the transition to lower global warming potential (GWP) products. Whether being used in immersion cooling applications, industrial cooling, or throughout the entire cold chain, Chemours Opteon™ products offer a strong sustainability profile, and excellent performance properties across a broad range of applications.

For more information visit Opteon.com.

About The Chemours Company
The Chemours Company (NYSE: CC) is a global leader in Titanium Technologies, Thermal & Specialized Solutions, and Advanced Performance Materials providing its customers with solutions in a wide range of industries with market-defining products, application expertise and chemistry-based innovations. We deliver customized solutions with a wide range of industrial and specialty chemicals products for markets, including coatings, plastics, refrigeration and air conditioning, transportation, semiconductor and consumer electronics, general industrial, and oil and gas. Our flagship products are sold under prominent brands such as Ti-Pure™, Opteon™, Freon™, Teflon™, Viton™, Nafion™, and Krytox™. The company has approximately 6,600 employees and 29 manufacturing sites serving approximately 2,900 customers in approximately 120 countries. Chemours is headquartered in Wilmington, Delaware and is listed on the NYSE under the symbol CC.

For more information, we invite you to visit chemours.com or follow us on Twitter @Chemours or LinkedIn.

Forward-Looking Statements
This press release contains forward-looking statements, within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, which involve risks and uncertainties. Forward-looking statements provide current expectations of future events based on certain assumptions and include any statement that does not directly relate to a historical or current fact. The words "believe," "expect," "will," "anticipate," "plan," "estimate," "target," "project" and similar expressions, among others, generally identify "forward-looking statements," which speak only as of the date such statements were made. These forward-looking statements may address, among other things, the outcome or resolution of any pending or future environmental liabilities, the commencement, outcome or resolution of any regulatory inquiry, investigation or proceeding, the initiation, outcome or settlement of any litigation, changes in environmental regulations in the U.S. or other jurisdictions that affect demand for or adoption of our products, anticipated future operating and financial performance for our segments individually and our company as a whole, business plans, prospects, targets, goals and commitments, capital investments and projects and target capital expenditures, plans for dividends or share repurchases, sufficiency or longevity of intellectual property protection, cost reductions or savings targets, plans to increase profitability and growth, our ability to make acquisitions, integrate acquired businesses or assets into our operations, and achieve anticipated synergies or cost savings, all of which are subject to substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. Forward-looking statements are based on certain assumptions and expectations of future events that may not be accurate or realized, such as full year guidance relying on models based upon management assumptions regarding future events that are inherently uncertain. These statements are not guarantees of future performance. Forward-looking statements also involve risks and uncertainties that are beyond Chemours' control. Matters outside our control, including general economic conditions and the COVID-19 pandemic, have affected or may affect our business and operations and may or may continue to hinder our ability to provide goods and services to customers, cause disruptions in our supply chains such as through strikes, labor disruptions or other events, adversely affect our business partners, significantly reduce the demand for our products, adversely affect the health and welfare of our personnel or cause other unpredictable events. Additionally, there may be other risks and uncertainties that Chemours is unable to identify at this time or that Chemours does not currently expect to have a material impact on its business. Factors that could cause or contribute to these differences include the risks, uncertainties and other factors discussed in our filings with the U.S. Securities and Exchange Commission, including in our Quarterly Report on Form 10-Q for the quarter ended June 30, 2023 and in our Annual Report on Form 10-K for the year ended December 31, 2022. Chemours assumes no obligation to revise or update any forward-looking statement for any reason, except as required by law.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

INVESTORS
Brandon Ontjes
VP, Financial Planning & Analysis and Investor Relations
+1.302.773.3300
investor@chemours.com

Kurt Bonner
Manager, Investor Relations, Chemours
+1.302.773.0026
investor@chemours.com

NEWS MEDIA
Thom Sueta
Director of Corporate Communications, Chemours

+1.302.773.3903
media@chemours.com

investor@chemours.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Clarity AI Honored in Fast Company Magazine’s 2023 “Brands That Matter” List4.10.2023 10:24:00 EEST | Press release

Clarity AI, the leading sustainability technology platform, has been named to Fast Company’s prestigious annual list of “Brands That Matter” in 2023. With this list, Fast Company, the world's leading business media brand, aims to get beyond “corporate vision statements and management talking points” and recognize brands that “clearly generate enthusiasm among their customers, offering a model of what other brands should be aiming for, and what a brand, at its best, can achieve.” Clarity AI was selected among more than 1,000 entries for its contribution to allowing “companies, investors, and more to ensure they’re investing sustainably by tracking metrics ranging from data on the climate impact to gender equality and diversity on the executive boards of prominent companies.” Additionally, Fast Company highlights Clarity AI’s role in “improving artificial technologies and understanding the multitude of benefits they can offer.” Rebeca Minguela, Founder & CEO of Clarity AI, said: “We're h

Uusi kysely: 66% suomalaisista työntekijöistä haluaisi kotona työskentelystä lain suojaaman oikeuden4.10.2023 10:00:00 EEST | Tiedote

Yhteistyötä tukevia ratkaisuja tarjoavan tekniikkayrityksen Owl Labsin hiljattain toteuttama kysely selvittää pohjoismaisten työntekijöiden asennoitumista etätyöhön. The State of Hybrid Work Report 2023 -tutkimukseen osallistui 2 000 vastaajaa Suomesta, Ruotsista, Norjasta ja Tanskasta. Raportista selviää, että peräti 66% suomalaisista työntekijöistä haluaisi etätyöstä tehtävän lain suojaaman oikeuden. Tämä kertoo joustavien työolojen kasvavasta suosiosta. Tutkimuksen mukaan 63% kaikista pohjoismaisista työntekijöistä on samaa mieltä oikeudesta etätyöhön. Tuki etätyölle laillisena oikeutena jakautuu eri Pohjoismaissa seuraavasti: 65% ruotsalaisista, 63% norjalaisista ja 57% tanskalaisista työntekijöistä tukee ajatusta. Owl Labsin toimitusjohtaja Frank Weishaupt sanoo: “Pohjoismaisten työntekijöiden yksimielisyys kotona työskentelystä lain suojaamana oikeutena kertoo muutoksista työntekijöiden asenteissa työympäristöään kohtaan. Se vahvistaa, miten tärkeänä työn ja vapaa-ajan välistä ta

ABN AMRO and Motive Partners form strategic partnership4.10.2023 09:30:00 EEST | Press release

The move demonstrates a joint commitment from two sizable financial technology investors to support continued innovation and growth in the evolving fintech landscape. Motive Ventures, the early-stage venture arm of Motive Partners, will manage the ABN AMRO Ventures Fund (AAV), consisting of 15 early-stage companies. In addition, ABN AMRO will become a significant investor in Motive-managed vehicles. With funding in the financial services industry declining by 70% between 2021 and 2022, and numerous venture capitalists reducing their investment programmes, Motive Partners and ABN AMRO are charting a new course. Their partnership unites two leading venture platforms, each with decades of fintech expertise and a dedication to innovation in both financial services and venture capital. Their goal is to strengthen the fintech sector and boost innovation by bringing Motive Partners’ ecosystem and experts to the AAV portfolio and ABN AMRO’s broader network. Motive Ventures’ portfolio consists

Desktop Health Announces that Flexcera™ Smile Ultra+ is now Available in Europe, Following Recent Class IIa MDR Certification by the European Union4.10.2023 09:00:00 EEST | Press release

Desktop Health™, the trusted health care brand of Desktop Metal (NYSE:DM), announced that its popular Flexcera™ Smile Ultra+ dental resin, for 3D printing permanent and temporary restorations, is now available for purchase in Europe following its successful certification as a Class IIa medical device under the European Union Medical Device Regulation (MDR). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20231004075864/en/ Desktop Health's Flexcera™ Smile Ultra+ dental resin for 3D printing permanent and temporary restorations is now available for purchase in Europe following its successful certification as a Class IIa medical device under the European Union Medical Device Regulation (MDR). (Photo: Business Wire) Flexcera Smile Ultra+ delivers exceptional strength, life-like aesthetics, and the long-term performance expected from a permanent restoration material. Already an FDA 510(k) Class II cleared material, Flexcera Smile U

Velsera to Showcase Seven Bridges Bioinformatics Platform at BioTechX Europe4.10.2023 08:03:00 EEST | Press release

Velsera, a global healthcare technology company offering a universal software platform to connect clinical care with discovery, is proud to announce its title sponsorship at BioTechX Europe in Basel, Switzerland, where it will showcase its industry-leading Seven Bridges bioinformatics platform. This conference is Europe’s largest congress covering diagnostics, precision medicine and digital transformation in pharmaceutical development and healthcare. One of the keynote presentations, sponsored by Velsera, will be on the topic of “Digital Transformation of Early Research at Novo Nordisk and Leveraging AI/ML for Drug Discovery", featuring Asli Ismihan Ozen, head of research engineering, digital science and innovation at Novo Nordisk. She takes the stage at 9:20 am on Wednesday, Oct. 4. Additionally, Jack DiGiovanna, Velsera’s senior vice president of science strategy, will present on “Unleashing the Power of Neoantigens”, with an insightful look at solving complex problems through intero

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom